Royalty Pharma Revenue vs. Net Income
| RPRX Stock | USD 44.88 0.22 0.49% |
Total Revenue | First Reported 2000-03-31 | Previous Quarter 609.3 M | Current Value 622 M | Quarterly Volatility 280.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.75 | 0.9 |
|
| |||||
| Net Profit Margin | 0.54 | 0.3242 |
|
| |||||
| Operating Profit Margin | 0.7 | 0.6558 |
|
| |||||
| Pretax Profit Margin | 0.73 | 0.5568 |
|
| |||||
| Return On Assets | 0.0779 | 0.0393 |
|
| |||||
| Return On Equity | 0.2 | 0.119 |
|
|
For Royalty Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Royalty Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Royalty Pharma Plc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Royalty Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Royalty Pharma Plc over time as well as its relative position and ranking within its peers.
Royalty Pharma's Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Royalty Pharma Revenue Breakdown by Earning Segment
By analyzing Royalty Pharma's earnings estimates, investors can diagnose different trends across Royalty Pharma's analyst sentiment over time as well as compare current estimates against different timeframes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty Pharma. Anticipated expansion of Royalty directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Royalty Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.09 | Dividend Share 0.88 | Earnings Share 1.78 | Revenue Per Share | Quarterly Revenue Growth 0.048 |
Understanding Royalty Pharma Plc requires distinguishing between market price and book value, where the latter reflects Royalty's accounting equity. The concept of intrinsic value - what Royalty Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Royalty Pharma's price substantially above or below its fundamental value.
It's important to distinguish between Royalty Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Royalty Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Royalty Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Royalty Pharma Plc Net Income vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Royalty Pharma's current stock value. Our valuation model uses many indicators to compare Royalty Pharma value to that of its competitors to determine the firm's financial worth. Royalty Pharma Plc is rated below average in revenue category among its peers. It is rated below average in net income category among its peers making up about 0.32 of Net Income per Revenue. The ratio of Revenue to Net Income for Royalty Pharma Plc is roughly 3.08 . At this time, Royalty Pharma's Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Royalty Pharma's earnings, one of the primary drivers of an investment's value.Royalty Revenue vs. Competition
Royalty Pharma Plc is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 84.83 Billion. Royalty Pharma holds roughly 2.38 Billion in revenue claiming about 2.8% of equities under Health Care industry.
Royalty Net Income vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Royalty Pharma |
| = | 2.38 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Royalty Pharma |
| = | 770.95 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Royalty Net Income Comparison
Royalty Pharma is currently under evaluation in net income category among its peers.
Royalty Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Royalty Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Royalty Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Royalty Pharma's change in net profit over the period of time. It can combine multiple indicators of Royalty Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 72.5 K | 68.8 K | |
| Operating Income | 1.6 B | 1.3 B | |
| Net Income From Continuing Ops | 1.3 B | 1.2 B | |
| Income Before Tax | 1.3 B | 1.3 B | |
| Total Other Income Expense Net | -235.3 M | -223.6 M | |
| Net Income Applicable To Common Shares | 49.3 M | 46.8 M | |
| Net Income | 770.9 M | 1.1 B | |
| Income Tax Expense | 553.2 M | 493.7 M | |
| Net Interest Income | -274.1 M | -287.8 M | |
| Interest Income | 33.6 M | 44.9 M | |
| Non Operating Income Net Other | 99.9 M | 93.7 M | |
| Change To Netincome | 57.7 M | 60.6 M | |
| Net Income Per Share | 1.79 | 2.62 | |
| Income Quality | 3.23 | 1.96 | |
| Net Income Per E B T | 0.58 | 0.75 |
Royalty Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Royalty Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Royalty Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Royalty Pharma's important profitability drivers and their relationship over time.
Royalty Pharma Earnings Estimation Breakdown
The calculation of Royalty Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Royalty Pharma is estimated to be 1.2908 with the future projection ranging from a low of 1.2615 to a high of 1.32. Please be aware that this consensus of annual earnings estimates for Royalty Pharma Plc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.26 Lowest | Expected EPS | 1.32 Highest |
Royalty Pharma Earnings Projection Consensus
Suppose the current estimates of Royalty Pharma's value are higher than the current market price of the Royalty Pharma stock. In this case, investors may conclude that Royalty Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Royalty Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 10 | 77.03% | 0.0 | 1.2908 | 1.78 |
Royalty Pharma Earnings per Share Projection vs Actual
Actual Earning per Share of Royalty Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Royalty Pharma Plc predict the company's earnings will be in the future. The higher the earnings per share of Royalty Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Royalty Pharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Royalty Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Royalty Pharma should always be considered in relation to other companies to make a more educated investment decision.Royalty Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Royalty Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2026-02-11 | 2025-12-31 | 1.5 | 0.38 | -1.12 | 74 | ||
2025-11-05 | 2025-09-30 | 1.04 | 1.17 | 0.13 | 12 | ||
2025-08-06 | 2025-06-30 | 1.03 | 1.14 | 0.11 | 10 | ||
2025-05-08 | 2025-03-31 | 0.95 | 1.06 | 0.11 | 11 | ||
2025-02-11 | 2024-12-31 | 0.25 | 0.35 | 0.1 | 40 | ||
2024-11-06 | 2024-09-30 | 0.93 | 0.92 | -0.01 | 1 | ||
2024-08-08 | 2024-06-30 | 0.97 | 0.96 | -0.01 | 1 | ||
2024-05-09 | 2024-03-31 | 0.98 | 0.98 | 0.0 | 0 | ||
2024-02-15 | 2023-12-31 | 1 | 1.52 | 0.52 | 52 | ||
2023-11-08 | 2023-09-30 | 0.77 | 0.79 | 0.02 | 2 | ||
2023-08-08 | 2023-06-30 | 0.81 | 0.84 | 0.03 | 3 | ||
2023-05-09 | 2023-03-31 | 1.27 | 1.6 | 0.33 | 25 | ||
2023-02-15 | 2022-12-31 | 1.46 | 1.56 | 0.1 | 6 | ||
2022-11-08 | 2022-09-30 | 0.71 | 0.73 | 0.02 | 2 | ||
2022-08-04 | 2022-06-30 | 0.78 | 0.79 | 0.01 | 1 | ||
2022-05-05 | 2022-03-31 | 0.72 | 0.6 | -0.12 | 16 | ||
2022-02-15 | 2021-12-31 | 0.78 | 0.8 | 0.02 | 2 | ||
2021-11-10 | 2021-09-30 | 0.7 | 0.73 | 0.03 | 4 | ||
2021-08-11 | 2021-06-30 | 0.71 | 0.71 | 0.0 | 0 | ||
2021-05-11 | 2021-03-31 | 0.65 | 0.67 | 0.02 | 3 | ||
2021-02-17 | 2020-12-31 | 0.7 | 0.7 | 0.0 | 0 | ||
2020-11-10 | 2020-09-30 | 0.59 | 0.65 | 0.06 | 10 | ||
2020-08-12 | 2020-06-30 | 0.6 | 0.61 | 0.01 | 1 | ||
2020-06-17 | 2020-03-31 | 0.52 | 3.94 | 3.42 | 657 | ||
2017-09-30 | 2017-09-30 | -0.28 | -0.05 | 0.23 | 82 | ||
2017-06-30 | 2017-06-30 | -0.22 | -0.08 | 0.14 | 63 | ||
2017-03-31 | 2017-03-31 | -0.14 | -0.22 | -0.08 | 57 | ||
2016-12-31 | 2016-12-31 | -0.17 | -0.16 | 0.01 | 5 |
Use Royalty Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Royalty Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Royalty Pharma will appreciate offsetting losses from the drop in the long position's value.Royalty Pharma Pair Trading
Royalty Pharma Plc Pair Trading Analysis
The ability to find closely correlated positions to Royalty Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Royalty Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Royalty Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Royalty Pharma Plc to buy it.
The correlation of Royalty Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Royalty Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Royalty Pharma Plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Royalty Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Royalty Pharma position
In addition to having Royalty Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Government Funds Thematic Idea Now
Government Funds
Funds or Etfs that invest in fixed income securities issued by national government to finance government spending or to facilitate Federal Reserve monetary policies. The Government Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Government Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.